1Q EARNINGS: Teva, Mylan differ on generic Copaxone entry
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and Mylan delivered revenue growth across large portfolios of generic and branded medicines during the first quarter, but executives from both companies spent most of their quarterly conference calls on 1 May talking about one product: Copaxone.